ProShare Advisors
CGEM icon

ProShare Advisors’s Cullinan Oncology CGEM Stock Holding History

ProShare Advisors’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$149K Sell
10,465
-2,024
-16% -$26K ﹤0.01% 1651
2025
Q4 		$129K Buy
12,489
+1,661
+15% +$15K ﹤0.01% 1822
2025
Q3 		$64.2K Sell
10,828
-1,837
-15% -$13.5K ﹤0.01% 1904
2025
Q2 		$95.4K Sell
12,665
-1,288
-9% -$10.3K ﹤0.01% 1888
2025
Q1 		$106K Sell
13,953
-3,373
-19% -$32.4K ﹤0.01% 1822
2024
Q4 		$211K Buy
17,326
+4,124
+31% +$59.3K ﹤0.01% 1858
2024
Q3 		$221K Buy
+13,202
New +$234K ﹤0.01% 1669
2022
Q1 		– Sell
-11,810
Closed -$183K – 2223
2021
Q4 		$183K Buy
+11,810
New +$236K ﹤0.01% 2067

Other funds holding CGEM

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.58B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $369M AUM 78.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return